Cagrilintide

Cagrilintide is an engineered peptide modeled on the pancreatic hormone amylin. It has been investigated for effects on appetite, body weight, and glucose regulation, including in combination with GLP-1 receptor agonists.

Pancreatic cells release amylin alongside insulin, and its physiological functions include signaling fullness and contributing to glucose regulation after food intake. The guide links altered amylin signaling with metabolic difficulties, but its broad explanation should not be taken to establish a universal cause of obesity or disturbed appetite.

Mechanistic topics described in the guide include amylin-like effects on fullness signaling, appetite, and the rate at which food leaves the stomach. These processes are relevant to investigations of food intake and post-meal glucose responses. Complementary activity with GLP-1 receptor agonists is also discussed, although the notes do not establish pharmacological synergy.

1. 01

   Molecular target

2. 02

   Cellular signal

3. 03

   Biological process

LEVEL 03 · Early human research

Small or early-stage human studies exist, with limited certainty and reproducibility.

Evidence levels reflect the state of documented research only. They are not rankings of popularity, quality or suitability, and a higher level never implies that a compound is an approved medicine.

The source guide presents cagrilintide as a candidate for weight management and metabolic research. It attributes potential benefits to reduced hunger, altered gastric transit, and complementary effects with GLP-1-based therapies. The guide also characterizes trial tolerability favorably, but provides no study-level details in the supplied notes to support an independent assessment.

Source: The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Summarised in our own wording from the cited reference. The reference is a popular guide, not peer-reviewed literature; its statements are reported here as source claims rather than established facts.

Dosage, reconstitution and administration guidance is deliberately excluded from this platform.

The notes do not establish the durability of weight-related outcomes, the magnitude of glycemic effects, or whether combination effects exceed additivity. Their non-peer-reviewed origin and absence of identifiable trial details limit confidence in the stronger claims.

The guide identifies nausea, constipation, and other digestive symptoms as reported adverse effects, while describing them as generally temporary. Safety data are limited in the supplied material, and the favorable summary does not establish long-term safety or applicability across populations. This information is not medical advice.

Research-stage compound unless otherwise established by a competent authority. Regulatory classification differs between jurisdictions and can change over time; nothing here indicates marketing authorisation.

Primary reference for this entry:

The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Suggested literature search terms taken from the source. They are search starting points, not citations to specific studies.

• “Cagrilintide and GLP-1 agonist synergy in weight loss”
• “Cagrilintide clinical trials for Type 2 diabetes”
• “Amylin analogs in metabolic health and obesity management”

Editorial status

source reviewed

Last updated

2026-09-14

Last reviewed

2026-09-13

Language

EN